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BACKGROUND:PerWHO, 2000 classification, pancreaticmucinous cystic neoplasms (MCN) are
defined by presence of ovarian stroma, and are primarily located in the pancreatic body/tail of
females. The incidence of MCN and associated malignancy in males, since, standardization of
MCN diagnostic-criteria is unknown.
METHODS: MCN resections from 2000 to 2014 at eight institutions of the Central-Pancreas-
Consortium were included, and divided into early (2000-2007) and late (2008-2014) time-
periods. Primary aim was to characterize MCN and associated adenocarcinoma/high-grade-
dysplasia (AC/HGD) in males versus females over time.
RESULTS:Of 1667 resections for pancreatic cystic lesions, 349 pts (21%) hadMCNs: 310 (89%)
female, 39 (11%) male. Patients were equally divided between early (n = 173) and late (n = 176)
time-periods.MCN inmale-patients decreased over time (early: 15%, late: 7%; P = 0.036), as did
pancreatic head/neck location (early: 22%, late: 11%; P = 0.01). MCN-associated AC/HGDwas
more frequent in males versus females (39 vs. 12%; P < 0.001). The overall rate of MCN-
associated AC/HGD remained stable (early: 17%, late: 13%; P = 0.4), and was identical in males
(39%) over both time-periods. Males with AC/HGD had more LN-positive disease versus
females (57 vs. 22%; P = 0.039).
CONCLUSIONS:As the diagnostic-criteria of MCN have standardized over time, MCN diagnosis
has decreased in males and head/neck location. Despite this, MCN-associated adenocarci-
noma/high-grade dysplasia has been stable and remains high inmales. Anymalewith suspected
MCN, regardless of location, should undergo resection.
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1 | INTRODUCTION
Cystic neoplasms of the pancreas are a rare and assorted group of
pancreatic lesions that display a variety of clinical and pathologic
characteristics, and carry a range of malignant potential. They
represent approximately 10% of all pancreatic neoplasms, but account
for nearly one third of all pancreatic resections.1 In addition to serous
cystadenomas and intraductal papillary mucinous neoplasms (IPMNs),
mucinous cystic neoplasms (MCNs) are one of themost common cystic
neoplasms of the pancreas.2,3
Current guidelines recommend complete resection of all suspected
MCNs due to the risk of associated high-grade dysplasia and invasive
adenocarcinoma, which ranges between 10% to as high as 46% in the
literature.3–9 Thus, achieving an accurate diagnosis ofMCN is paramount,
yet can be difficult due to the often overlapping clinical, radiographic,
cytologic, and histopathologic featureswith branch-duct IPMNs. In 2000,
as part of an effort to better differentiate MCN from IPMN, the World
Health Organization (WHO) defined MCN by the presence of ovarian
stromaonhistopathology.10While thishistologicdistinctionhashelped to
standardize the pathologic diagnosis of MCN, the clinical, radiographic,
and endoscopic characteristics of these lesions remain important pre-
operative diagnostic tools for determining management strategy.
One of the most striking clinical features unique to MCNs is that
they occur almost exclusively in the pancreatic body and tail of
premenopausal women.4,7 Still, based on the 2000 WHO criteria,
MCNs do occur in males, and male gender has been associated with a
higher malignant potential, yet these patients are a group that has
largely been unstudied.8,11–13 The purpose of this study was utilize a
large, multi-institutional database to characterize MCNs and assess
the incidence of associated adenocarcinoma/high-grade dysplasia
(AC/HGD) in males compared to females over time.
2 | METHODS
The Central Pancreas Consortium is a collaboration of eight U.S.
academic institutions: Emory University, Northwestern University,
University of Cincinnati, University of Louisville, University of North
Carolina, University of Wisconsin, Vanderbilt University, and
Washington University in St. Louis. All patients who underwent
resection of a pancreatic cystic neoplasm from 2000 to 2014 were
assessed. Only patients with pathologically confirmed MCN were
included in analysis. Patients with other pancreatic cystic neoplasms
were excluded. Pertinent baseline demographic, perioperative, and
pathologic data were reviewed retrospectively using patient charts.
Pathologic review was performed by experienced GI pathologists at
each institution at the time of resection. Institutional Review Board
approval was obtained at each institution prior to data collection.
The primary objective was to compare the clinical, radiographic, and
pathologic characteristics of MCNs in male versus female patients. The
secondary objectiveswere to compare the incidence ofMCNs diagnosed
in male patients, located in the head and neck of the pancreas, and
associated with AC/HGD over two time periods: early (2000-2007) and
late (2008-2014). These timeperiodswere chosen to ensure equal cohort
size. In addition, basedon thewell-knownobservation that it takes several
years for published data and guidelines to be widely adopted into clinical
practice,14 the authors believed that 8 years was an appropriate time-
frame to assess changes in diagnostic patterns.
Statistical analyses were conducted using SPSS 22.0 software
(IBM Inc., Armonk, NY). Male and female patients who underwent
pancreatic resection for MCN were compared using chi-squared
analysis for categorical variables, and Student's t-test for continuous
variables. Statistical significance was predefined as two-tailed P < 0.05.
3 | RESULTS
Of 1667 patients who underwent resection of a pancreatic cystic
neoplasm, 349 (21%) had MCNs. The remaining cystic neoplasms that
were excluded from analysis were: IPMN (n = 586), serous cystade-
noma (n = 227), cystic adenocarcinoma (n = 132), pseudocyst (n = 122),
pseudopapillary tumor (n = 86), and other (n = 165).
Of the 349 MCN patients, 310 (89%) were female and 39 (11%)
were male. Clinicopathologic comparisons between male and female
patients are shown in Table 1. Male patients were older than female
patients (65 yrs vs. 52 yrs; P < 0.001), and were more likely to present
with jaundice (11 vs. 1%; P = 0.001), have lesions located in the head of
the pancreas (49 vs. 11%; P < 0.001), and display pancreatic ductal
dilatation on pre-operative imaging (42 vs. 14%; P < 0.001). Male
patients also more frequently underwent pancreaticoduodenectomy
compared to female patients (46 vs. 10%; P < 0.001), although distal
pancreatectomy was still the most common procedure performed in
both groups. Adenocarcinoma and/or high-grade dysplasia was
identified within surgical specimens in 39% of male patients and 12%
of female patients (P < 0.001). Lymph node positive disease was
identified in 57%ofmale patients and22%of female patients (P = 0.04).
Patients were divided by surgery date into early (2000-2007;
n = 173, 50%) and late (2008-2014; n = 176, 50%) time periods (Fig. 1).
There was a decrease from the Early to Late time periods in the
proportion ofMCN patients whoweremale (15 vs. 7%; P = 0.04) and of
MCNs located in the pancreatic head/neck (22 vs. 11%; P = 0.01). There
was no difference in the proportion ofMCNs associated with AC/HGD
between the early and late groups (17 vs. 13%; P = 0.41). On stratum-
specific analysis by gender, the proportion of male MCN patients with
associated AC/HGD remained stable at 39% over both time periods.
4 | DISCUSSION
Mucinous cystic neoplasms are one of the most common types of
cystic neoplasms of the pancreas, and are primarily found in the
pancreatic body and tail of premenopausal women.1,2 Although
uncommon, MCNs are still reported in males, even using modern
diagnostic criteria, yet few studies focus on this rare and unique group
of patients.11–13 In this study, we utilized a large, multi-institutional
database to investigate the clinicopathologic characteristics of MCNs
diagnosed in male compared to female patients, and assessed
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diagnostic trends over time. We found that male patients were more
likely to present with obstructing head/neck lesions and have
associated AC/HGD compared to females. While the proportion of
male MCN patients and lesions located in the pancreatic head/neck
decreased over time, the incidence of AC/HGD remained stable, and
was particularly high among male patients.
Because of the relatively high risk of associated AC/HGD,
complete surgical resection is recommended for all suspected
MCNs.4 Thus, distinguishing MCNs from branch-duct IPMNs, which
carry a lower malignant potential and do not always necessitate
surgical excision, is important. One of the most striking differences
between the two lesions is that the overwhelming majority of MCNs
occur in the pancreatic body and tail of female patients, while branch-
duct IPMNs occur more commonly in the pancreatic head and neck
with a nearly even gender distribution.4,7 Since 2000, when theWHO
proposed the presence of ovarian stroma as the defining diagnostic
criterion for MCN, the association between MCN and female gender
has become even stronger. In a systematic review of 25 studies
published from 1996 to 2005, Goh et al.15 found that in studies in
which the presence of ovarian stroma was not mandatory for MCN
diagnosis, 80% (range, 8-100%) were female patients. In studies, in
which the presence of ovarian stroma was mandatory for MCN
diagnosis, however, 99.7% (range, 98-100%) were female.
This finding has led some to adopt the belief that MCNs are exclusive
to only female patients, and anymale patientwith anMCNdiagnosis likely
has a misclassified IPMN. Yet the continued emergence of modern case
reports and case series ofmale patientswith histologically confirmedMCN
basedonthepresenceofovarianstroma,demonstrates that,while rare, this
populationdoes, in fact, exist.11–13,16,17Although the specific pathogenesis
ofMCNs is unclear, it is believed to be hormonallymediated, and in a study
by Regi et al.,16 nearly 50% of the male patients with histologically
confirmedMCNwere found to have hormonal and/or sexual dysfunction.
Furthermore, MCNs in male patients are of particular importance due to
their increasedmalignantpotential. As thecurrent authorsdemonstrated in
a previous study,8 male gender was independently associated with the
presenceofAC/HGDonpathology, evenwhen taking into account patient
comorbidities and other diagnostic features.
TABLE 1 Clinicopathologic characteristics of male versus female
patients with mucinous cystic neoplasms
Variable
Female
(n = 310,
89%)
Male
(n = 39,
11%)
P-
value
Age (yrs), mean ± SD 52 ± 14 65 ± 12 <0.001
BMI (kg/m2), mean ± SD 29 ± 7 27 ± 8 0.35
Race, n (%)
White 241 (78) 35 (90) 0.46
African-American 53 (17) 4 (10)
Latino 5 (2) 0 (0)
Other 11 (3) 0 (0)
ASA class, n (%)
1 68 (24) 9 (24) 0.31
2 132 (46) 12 (32)
3 81 (28) 16 (43)
4 6 (2) 0 (0)
Presentation, n (%)
Asymptomatic 108 (35) 14 (37) 0.001
Jaundice 3 (1) 4 (11)
Pain 147 (48) 11 (29)
Pancreatitis 33 (11) 6 (16)
Other 15 (6) 3 (8)
Radiographic appearance, n
(%)
Location (head/neck) 33 (11) 18 (49) <0.001
Septations 106 (40) 8 (25) 0.14
Solid component 51 (20) 4 (14) 0.62
Mural nodule 23 (9) 5 (17) 0.29
Ductal dilatation 36 (14) 14 (42) <0.001
Tumor size (cm), mean± SD 5.1 ± 4.2 3.5 ± 2.7 0.04
Resection, n (%)
Distal pancreatectomy 268 (87) 21 (54) <0.001
Pancreaticoduodenectomy 32 (10) 18 (46)
Central pancreatectomy 6 (2) 0 (0)
Total pancreatectomy 4 (1) 0 (0)
Technique, n (%)
Open 193 (62) 34 (87) 0.004
Minimally invasive 117 (38) 5 (13)
Estimated blood loss (mL),
mean ± SD
297 ± 318 494
± 424
0.001
Length of stay (days), mean
± SD
7.0 ± 4.6 11.9
± 13.5
0.002
Tumor size (cm), mean ± SD 5.2 ± 4.5 3.7 ± 2.6 0.004
Adenocarcinoma or high-
grade dysplasia, n (%)
37 (12) 15 (39) <0.001
Margin, n (%)
R0 293 (98) 36 (92) 0.10
R1 7 (2) 3 (8)
Lymph node positive, n (%) 6 (22) 8 (57) 0.04
BMI, body mass index; ASA, American Society of Anesthesiology.
FIGURE 1 Comparison of gender, lesion location, and malignant
potential over two time periods: early (2000–2007) and late
(2008–2014)
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Of the 349 patientswithMCNs in the current study, 310 (89%)were
female and 39 (11%) were male. Male patients were more likely to have
obstructing lesions in the pancreatic head/neck, and have associatedAC/
HGD compared to female patients. Understanding that this study was
performed based on retrospective chart review without centralized
pathologic re-review, it is possible that some of theseMCNs, particularly
in male patients and those diagnosed early on, may have been
misclassified branch-duct IPMNs. Allowing 8 years for the 2000 WHO
guidelines to integrate into clinical practice, we divided the cohort into
early (2000-2007) and late (2008-2014) groups. As expected, the
incidence ofmale gender and lesions located in the pancreatic head/neck
each decreased by 50% from the early to late time periods. Furthermore,
the incidence ofmale gender in the late time period (7%) fell more closely
in line with the incidence quoted in most modern studies (5%).4,7
Importantly, however, therewas no change in the incidence of associated
AC/HGD overall between the time periods, and it remained alarmingly
high specifically inmale patients (39%) in both the early and late groups. It
is unclear whether this observation represents distinct pathogenesis or
more aggressive tumor biology in male compared to female patients with
MCN. Regardless, taking a pragmatic approach, this study demonstrates
that, even in a modern era nearly a decade after the WHO criteria were
published, male patients are still being diagnosed with MCN and are at
high risk for AC/HGD. Thus, any male patient with suspected MCN,
regardless of location, should undergo resection.
There are several limitations to this study. As previously mentioned,
the retrospective nature of the study makes it challenging to draw
definitive conclusions. In addition, without centralized pathologic re-
review, histologic confirmationofMCNcouldnot bemade.However, this
study includes data from seven diverse, academic institutions across the
U.S., which eliminates single-institution bias and more closely represents
thediseasecharacteristics andgeneral practicepatternsof this country. In
addition, all involved academic centers have experienced GI pathologist
who performed the initial pathologic review.
5 | CONCLUSIONS
In conclusion, as the diagnostic-criteria of mucinous cystic neoplasms
(MCN)have standardizedover time,MCNdiagnosis hasdecreased inmale
patients and in the pancreatic head/neck. Despite this, MCN-associated
adenocarcinoma/high-grade dysplasia has been stable and remains
extremely high in male patients, even in the modern era. Thus, any male
patient with suspected MCN, with or without pre-operative histologic
confirmation and regardless of location, should undergo resection.
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